• Return to Headlines

Downgrade Alert for Momenta Pharmaceuticals (MNTA)

By Amy Schwartz

Momenta Pharmaceuticals (NASDAQ:MNTA) was downgraded from Hold to Sell at Maxim today. The stock closed yesterday at $11.83 on volume of 992,000 shares, above average daily volume of 507,000.

There is potential upside of 84.9% for shares of Momenta Pharmaceuticals based on a current price of $11.83 and an average consensus analyst price target of $21.88. The stock should find resistance at its 200-day moving average (MA) of $14.83, as well as support at its 50-day MA of $9.11.

In the past 52 weeks, Momenta Pharmaceuticals share prices have been bracketed by a low of $7.86 and a high of $25.56 and closed yesterday at $11.83, 51% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.2% while the 200-day MA has slid 1.8%.

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company specializes in sequencing and engineering of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. Momenta also develops technology-enabled generic products.

SmarTrend is tracking the current trend status for Momenta Pharmaceuticals and will alert subscribers who have MNTA in their portfolio or watchlist when shares have changed trend direction.

Keywords: analyst upgrades/downgrades momenta pharmaceuticals

Ticker(s): MNTA